Long term treatment with formoterol

  • Michael Rudolf
Conference paper


The important beneficial characteristics of formoterol can be summarised as follows:
  • 12 μg dose has speed of onset within 1–3 minutes and provides bronchodilatation for up to 12 hours

  • effective in nocturnal and exercise-induced asthma

  • 12 μg twice daily is effective and safe in treatment of patients with reversible airways obstruction

  • remains equally effective and safe after one year of continuous treatment

  • tolerability profile similar to short-acting beta2-agonists

  • no rebound increase in bronchial responsiveness after withdrawal of treatment

Regular treatment with formoterol 12 µg b.i.d. is therefore clearly indicated in moderate-to-severe asthma where patients are not well controlled on regular inhaled steroids and as-needed short-acting inhaled beta2-agonists. Whether or not formoterol should be used in patients with milder disease instead of increasing a low dose of inhaled steroid (as has been suggested by two recent studies with salmeterol [20, 21] remains debatable. However, for those patients who are having problems with inhaled steroids, or for whom nocturnal or exercise-induced symptoms persist despite otherwise good control, formoterol is certainly a reasonable alternative. These recommandations for the use of formoterol are fully in keeping with the indications for long-acting inhaled beta2-agonists suggested by the latest British guidelines on asthma management [22].


Rescue Medication Asthma Management Bronchial Responsiveness Clinical Trial Report Reversible Airway Obstruction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Global Initiative for Asthma (1995) Global strategy for asthma management and prevention. NHLBI/WHO Workshop report. National Institutes of Health, Publication 95–3659Google Scholar
  2. 2.
    Nelson HS (1995) Beta-adrenergic bronchodilators. N Engl J Med 333: 499–506PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson GP (1993) Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta2-adrenoceptor agonist bronchodilator. Life Sciences 52: 2145–60PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson GP (1993) Long-acting inhaled beta-adrenoceptor agonists; the comparative pharmacology of formoterol and salmeterol. New drugs in allergy and asthma 1993. Birkhäuser, Basel, pp 253–269Google Scholar
  5. 5.
    Clinical trial report DP/ON2. Data on file, CibaGoogle Scholar
  6. 6.
    Wallin A, Sandström T, Rosenhall L, Melander B (1993) Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 48: 611–614PubMedCrossRefGoogle Scholar
  7. 7.
    Clinical trial report DP/DF4. Data on file, CibaGoogle Scholar
  8. 8.
    Hendrick DJ, Brambilla R, Bromly CG (1995) Inhaled formoterol dry powder: duration of bronchodilator action following single dose. Eur Respir J 8 [Suppl 19]: 260sGoogle Scholar
  9. 9.
    Guerin JC, Germain M, Febvre N, Mairon N, Meyer F (1993) Protective effect of formoterol on exercise induced bronchoconstriction 10 hours after inhalation. Eur Respir J 6 [Suppl 7]: 201sGoogle Scholar
  10. 10.
    Steffensen I, Faurschou P, Riska H et al (1995) Inhaled formoterol dry powder in the treatment of patients with reversible obstuctive airways disease. Allergy 50: 657–663PubMedCrossRefGoogle Scholar
  11. 11.
    Maesen FPV (1995) Eformoterol versus salbutamol in patients with R.O.A.D. Br J Clin Pract (1995) [Suppl] 81: 8–10Google Scholar
  12. 12.
    Angus RM, Thomson NC (1995) Comparison of the efficacy and tolerability of eformoterol and salbutamol dry powder capsules for inhalation in elderly asthmatic patients. Thorax 50: 469 P - 470 PGoogle Scholar
  13. 13.
    Clinical trial report DP/RD4 (part of MT/A03). Data on file, CibaGoogle Scholar
  14. 14.
    Clauzel A, Lacoste J, Godard P et al (1994) Effect of formoterol powder on nocturnal wheezes. Eur Respir J 7 [Suppl 19]: 238sGoogle Scholar
  15. 15.
    Clincal trial report DP/NA1. Data on file, CibaGoogle Scholar
  16. 16.
    Burgess C, Ayson M, Rajasingham S et al (1994) The cardiovascular and metabolic effects of increasing doses of formoterol in patients with asthma. Eur Respir J 7 [Suppl 18]: 204sGoogle Scholar
  17. 17.
    Newnham D, Grove A, McDevitt D et al (1995) Subsensitivity of bronchodilator and systemic beta, adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 50: 497–504PubMedCrossRefGoogle Scholar
  18. 18.
    Yates DH, Sussman HS, Shaw MI et al (1995) Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir and Crit Care Med 152: 1170–74Google Scholar
  19. 19.
    Clinical trial report DP/OD1. Data on file, CibaGoogle Scholar
  20. 20.
    Woolcock A, Lundback B, Ringdal OLN et al (1994) Comparison of the effect of addition of salmeterol with doubling the inhaled steroid dose in asthmatic patients. Am J Respir Dis 149: A280Google Scholar
  21. 21.
    Greening AP, Ind PW, Northfield M et al (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids. Lancet 344: 219–224PubMedCrossRefGoogle Scholar
  22. 22.
    British Thoracic Society (1997) The British guidelines on asthma management. Thorax 52 [Suppl 1]: S 1-S 20Google Scholar

Copyright information

© Springer-Verlag/Wien 1998

Authors and Affiliations

  • Michael Rudolf
    • 1
  1. 1.University LondonUK

Personalised recommendations